Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/93930
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBalzan, R.-
dc.contributor.authorGalletly, C.-
dc.date.issued2015-
dc.identifier.citationFrontiers in Psychology, 2015; 6:967-1-967-6-
dc.identifier.issn1664-1078-
dc.identifier.issn1664-1078-
dc.identifier.urihttp://hdl.handle.net/2440/93930-
dc.description.abstractBACKGROUND: Psychotherapies for psychosis typically aim to develop an awareness of the implausible content of a delusion or target the underlying cognitive biases (i.e., problematic thinking styles, such as hasty decisions and illusory control) that foster and maintain delusional beliefs. A recently designed individual-based treatment entitled metacognitive therapy (MCT+) combines these two approaches. Emerging evidence suggests individualized MCT+, when used concurrently with antipsychotic medication, may be an effective psychological treatment for reducing delusional symptoms. However, it remains to be tested whether MCT+ can be effective in patients with active delusions who are not currently receiving psychotropic drugs. METHOD: We present two cases (one patient with schizophrenia and the other with delusional disorder) experiencing active delusions who underwent 4-weeks of intensive MCT+, without concurrent antipsychotic medication (minimum 6-months unmedicated). Baseline and 6-week follow-up data are presented on a variety of measures assessing delusion symptom severity (i.e., PANSS, PSYRATS, SAPS), clinical insight, and cognitive bias propensity. RESULTS: After 4-weeks of MCT+, both patients showed substantial reduction in delusional symptoms, reported improved clinical insight, and were less prone to making illusory correlations. CONCLUSIONS: The presented case studies provide preliminary evidence for the feasibility of MCT+ in treating patients not taking, or resistant to, antipsychotic medication.-
dc.description.statementofresponsibilityRyan P. Balzan, and Cherrie Galletly-
dc.language.isoen-
dc.publisherFrontiers Media-
dc.rights© 2015 Balzan and Galletly. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.-
dc.source.urihttp://dx.doi.org/10.3389/fpsyg.2015.00967-
dc.subjectschizophrenia-
dc.subjectpsychotherapy-
dc.subjectdelusions-
dc.subjectcognitive bias-
dc.subjectCBT-
dc.titleMetacognitive therapy (MCT+) in patients with psychosis not receiving antipsychotic medication: a case study-
dc.typeJournal article-
dc.identifier.doi10.3389/fpsyg.2015.00967-
pubs.publication-statusPublished-
dc.identifier.orcidBalzan, R. [0000-0003-2007-4317]-
dc.identifier.orcidGalletly, C. [0000-0001-6185-9677]-
Appears in Collections:Aurora harvest 2
Psychiatry publications

Files in This Item:
File Description SizeFormat 
hdl_93930.pdfPublished version177.84 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.